The investigational use of tPA for stroke

Thomas Brott, E. Clarke Haley, David E. Levy, William G. Barsan, Robert L. Reed, Charles P. Olinger, John R. Marler

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Stroke therapy trials have historically allowed for late patient entry (ie, within 24 to 48 hours from stroke onset) despite evidence suggesting the importance of early intervention. Experimental studies of cerebral infarction suggest treatment may be most effective when begun within three hours and may be only marginally effective when begun after 12 hours. Lysis of an acute intra-arterial thrombus in the setting of thrombolytic therapy is also time dependent. We describe an ongoing dose-escalation study of tissue plasminogen activator (tPA) as ultra-early therapy for cerebral infarction. The protocol requires that hemorrhage be ruled out by computed tomography scan of the brain prior to tPA infusion, and the infusion must begin within 90 minutes of symptom onset. The two primary goals of the study are to assess safety and potential efficacy. Preliminary results from the study and the future of ultra-early stroke intervention are discussed.

Original languageEnglish (US)
Pages (from-to)1202-1205
Number of pages4
JournalAnnals of emergency medicine
Issue number11
StatePublished - Nov 1988


  • stroke
  • use of tPA

ASJC Scopus subject areas

  • Emergency Medicine


Dive into the research topics of 'The investigational use of tPA for stroke'. Together they form a unique fingerprint.

Cite this